MRD-guided Treatment in NPM1mut AML Patients

NCT03769532 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

26

Enrollment

OTHER

Sponsor class

Stopped Feasibility

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Pembrolizumab
DRUG: Azacitidine

Sponsor

Technische Universität Dresden

Collaborators

[object Object]